Publication: Post-Hoc Analyses from the BEACON Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and T2DM

In BEACON, post hoc analyses demonstrated that treatment with bardoxolone methyl significantly reduced the risk of experiencing a composite renal endpoint consisting of ≥30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m², and end-stage renal disease (ESRD) events (provision of dialysis or kidney transplantation) compared to placebo.

  • Patients randomized to bardoxolone methyl were significantly less likely to experience the composite renal endpoint (hazards ratio 0.48 [95% CI 0.36-0.64]; p < 0.0001).
  • Patients randomized to bardoxolone methyl experienced mean increases in eGFR that were sustained through study week 48 and 4 weeks after cessation of treatment.